1Iskandar I, Richard D.Dipeptidyl peptidase - 4 inhibitors: a major new claas of oral antidiabetic drug[J] . Diabetes Obes Metab ,2007,9(2) : 153.
2James M, John W, Yun P, et al. Chronic inhibitor of dipeptidyl peptidase - 4 with a sitagliptin analog preserves pancreatic beta - cell mass and function in a rodent model pf type 2 diabetes[J] . Diabetes, 2006, 60(11):1 454.
3Baenett A. DPP - 4 in hibitors and the irpoten tialrolei the manageme ntoftype 2 diabetes[J] . Journal Clinical Practice, 2006,60(11) : 1 454.
4Herman G,Hanefeld M,Wu M,et al .Effect of MK - 043, a dipeptidyl peptidase - 4 (DPPIV) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes[J ] . Diabetes, 2005, 54(Suppl 1) : 131.
6Brazg R, Thomas K, Zhao P, et al. Effect of addng MK- 0431 to ongoing metform in therapy in type 2 diabetic patents who have inadequate glycaemic control on metformin[J ] . Diabetes, 2005,54(Suppl 1) :3.
7Nauck M, Meinininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor, sitagliptin, compared to the sulphonylurea glipizide in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double- blind, non - inferiority trial [J ]. Diabetes Obes Metab, 2007, 9 (2) : 194.
8Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial[J ] . Ann Intern Med, 2007,146(7) : 477.
9Pablo A, Carolyn M, Mark S, et al .Effect of the dipeptidyl peptidase - 4 inhibitor sitagliptin as monotherapy on glycemic control in patiens with type 2 diabetes[J ]. Diabetes Care, 2006,29(12) : 2 632.
10Saito YI, Otsuka Y. Substrate specificity of the nategl- inide/H( + )cotransport system for phenolic acids[J] . J Agric Food Chem, 2005, 5a(15). 6 100.
